Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

You Just Pocketed 89% From Our Recent Inflation Warning

We’ve been telling you folks for months that the pesky surge in prices we know as “inflation” has been showing up in different spots within the U.S. economy.

In early April, Shah Gilani – editor of our Capital Wave Forecast and Short Side Fortunes advisory services – told us that food prices were spiking. And he even re-recommended an “old friend”.

Folks who acted on that advice have pocketed a 27% gain in less than four months…

  • The Secret to Making Money from Bioscience's "Scariest Event"

    In bioscience investing, binary catalysts are milestone events that signal a thumbs-up or thumbs- down for an experimental drug as it makes its way through the regulatory process.

    Positive catalysts can send a share price soaring. Negative ones can send it into a nosedive.

    Perhaps the least  understood of these catalysts are FDA Advisory Committee (a.k.a. AdCom) recommendations.

    But they're also among the most powerful.

    Here's what I mean, and how to play them profitably... Full Story

    Read More...
  • The Four Telltale Signs of a Bioscience "Blockbuster" in the Making

    The FDA's Expedited Programs help get promising new therapies for seriously ill patients approved as soon as possible.

    But they also create an unintended side effect that's a huge advantage for investors: They point exactly to the biggest money-making opportunities in the bioscience industry.

    They're like big, green, neon signs that say, "This is an important drug with incredible profit potential."

    And this is how you find them... Full Story

    Read More...
  • Stocks to Buy: Why This Biopharma Company Is a “Long-Term Profit Machine” 20140509-stocks-to-buy-CARA

    One strategy experts use when looking for the best biotech stocks to buy is finding companies with promising drug candidates that are close to receiving regulatory approval. When these drugs hit the market, they can bring in billions in revenue.

    When companies have multiple promising drugs in their product pipeline, they become even more attractive because they have more than one shot at finding a revenue blockbuster.

    That’s why Money Morning’s Defense & Tech Specialist Michael A. Robinson likes this biotech stock to buy now…
  • Finding the Blockbuster That Will Make You Rich In the pharmaceutical industry, a "blockbuster" is any drug that brings in $1 billion or more in revenue per year. It's the prize that every biotech hopes to win - and every biotech investor hopes to cash in on. So how do you spot one in the making? If the market suspects a drug candidate has blockbuster potential, catalysts (events like positive clinical study results and regulatory milestones) will give its manufacturer's share price a big, big boost. There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search... Full story...
  • Double Your Money with Our "High-Tech GPS"

    Early last year, I saw a research study that said nearly 60% of all U.S. workers have a net worth of less than $25,000.

    And that means they have no retirement.

    From the moment that I saw that research, I knew I had a mission - to help folks reclaim their financial futures by breaking free of Wall Street's self-serving shackles... and creating wealth all on their own.

    And I knew there was one avenue to travel - the high-tech highway.

    So I developed a roadmap - a set of five rules - that would serve as a kind of "tech-investing GPS." My goal was to help investors identify "double-your-money" tech stocks - and navigate their way to massive high-tech wealth.

    Today I'm going to walk you through those rules again, and also give you a bonus - a biotech stock with double-your-money potential.

    So let's get started...
  • Three Bioscience Breakthroughs You Can't Afford to Miss You can make huge gains investing in a breakthrough drug, but you can do even better putting your money into a new, cutting-edge technology platform that can fuel a company's entire pipeline. One biotech I recommended to my BioScience Millionaire subscribers last July, Sangamo Biosciences Inc. (Nasdaq: SGMO), has developed a technology from naturally occurring molecules, called zinc finger proteins (ZFPs), that scientists can engineer to edit specific genes in the human genome. It can cut them out, replace them, or add new ones - in other words, it plays with the basic building blocks of life as if they were Lego pieces! Sangamo is currently using ZFP technology to find cures for some of the most intractable - and often un-druggable - diseases we know of, including HIV, Alzheimer's, Huntington's, and Down's syndrome to name a few. And Sangamo isn't the only company using ZFPs for research. In fact, it licenses out the technology to scientific institutions and companies all over the world - providing it with a great revenue stream. As a result, SGMO shares have gone up more than 150% since last summer. Actually, if you'd had the foresight to buy the stock at the beginning of 2012, you'd now be realizing profits of 577% on your money. The magic word in that sentence is "foresight." The trick is to spot these technologies early in their development, either before they've had IPOs or soon after. With that in mind, here are a few exciting new technologies to keep an eye on... Full Story Read More...
  • Penny Stocks to Watch Top 10 Penny Stocks this year

    The recent spate of uninspiring data, from unemployment to retail sales, has been blamed on the unrelenting cold and snowy winter. But one group that hasn't been affected, and isn't using the convenient "bad weather" excuse, is this list of penny stocks to watch now.

    This week brought huge gains from several low-priced stocks across all sectors:

    Here are four penny stocks to watch now.
  • Penny Stocks: Today's Biggest Movers Today's Penny Stock Earnings

    A number of penny stocks showed investors some love today (Friday) with huge share-price climbs.

    While the Dow Jones Industrial Average rose just under 1% by 2 p.m., these hot penny stocks were up double digits.

    Following are five of Friday's biggest low-priced movers.
  • Investing in Tech: We Sure Hope You Own These Three "Wealth Building Blocks"

    I get a lot of questions from you folks here at the Strategic Tech Investor.

    And the single most frequently asked query is this one:

    "Michael, what's the best way to get started as a tech investor?"

    I'll grant you: As questions go, that's probably the most basic one that you'll find.

    To continue reading, please click here...
  • Cadence Pharmaceuticals (Nasdaq: CADX) Stock Climbs 26% in Latest Biotech Deal Pharma

    What a year so far for biotech stock profits...

    Another consolidation in the active biotech sector came Tuesday when Cadence Pharmaceuticals Inc. (Nasdaq: CADX) agreed to be acquired by Mallinckrodt plc (NYSE: MNK) in a $1.3 billion deal. The move sent CADX up 26%.

    Under terms of the deal, Dublin, Ireland-based Mallinckrodt will pay $14 in cash for each share of San Diego, Calif.-headquartered Cadence. That's a 26% premium to Monday's closing price and a 32% premium to the stock's average 30-day trading price.

    To continue reading, please click here...
  • The Best Biotech Takeover Targets for 2014 cliff

    This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.

    The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.

    To continue reading, please click here...
  • IPO Calendar 2014 Dominated by Biotech best biotech investments 2014

    IPO Calendar 2014: This year is forecast to be a record year for initial public offerings (IPOs).

    Over the January to March period, some 250 to 300 new issues will launch, according to professional services firm EY - a number not seen since the start of the 2008 financial crisis.

    And biotech companies are the hottest issues to date.

    Since 2000, no two-week period saw more than six new biotech issues - until now.

    See which biotech IPOs could be the best investments now...
  • Furiex Pharmaceuticals (Nasdaq: FURX) Stock Up 130% Today on This "Blockbuster Drug" News

    While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.

    Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.

    To continue reading, please click here...
  • Best Penny Stocks: Why Biotech Keeps Delivering Triple-Digit Gains best biotech investments 2014 Some of the top biotech penny stocks we recommended last year gained as much as 440%, 231%, and 214%. And the biotech sector is going to keep surging - especially the sector's best low-priced buys. We've already identified some of this year's winners - With that in mind, following are three of the best penny stocks in biotech.
  • Hot Penny Stocks This Week

    A number of this year's hot penny stocks have soared by double digits since the New Year.

    Their meteoric moves have far outpaced the lukewarm (if any) gains of major benchmarks and their components. The Dow is down roughly 4% and the S&P is off nearly 3% year to date, after gains of 26% and 32% respectively in 2013. The Nasdaq was up 1% until Friday's broad-based selloff left the tech-heavy index down an equal amount for the year.

    To continue reading, please click here...